Unicycive Therapeutics (UNCY) Assets Average (2021 - 2026)

Unicycive Therapeutics (UNCY) has reported Assets Average for 6 consecutive years, with $68.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Assets Average rose 135.47% year-over-year to $68.2 million; the trailing twelve-month figure through Jun 2026 stood at $68.2 million (up 135.47% YoY), and the FY2025 full-year result was $40.4 million, up 76.2% from the prior year.
• Assets Average improved to $68.2 million in Q2 2026 per UNCY's latest filing, from $56.8 million in the prior quarter.
• Across five years, Assets Average topped out at $68.2 million in Q2 2026 and bottomed at $6.5 million in Q4 2022.
• Historically, Assets Average has averaged $31.1 million across 5 years, with a median of $29.4 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Assets Average tumbled 66.27% in 2022, then surged 158.81% in 2023.
• Over 5 years, Assets Average stood at $6.5 million in 2022, then soared by 158.81% to $16.8 million in 2023, then jumped by 108.85% to $35.1 million in 2024, then jumped by 42.0% to $49.9 million in 2025, then jumped by 36.78% to $68.2 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $68.2 million, $56.8 million, and $49.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.